A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Public ClinicalTrials.gov record NCT06091254. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)
Study identification
- NCT ID
- NCT06091254
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Enrollment
- 822 participants
Conditions and interventions
Conditions
Interventions
- Bendamustine Drug
- Cyclophosphamide Drug
- Doxorubicin Drug
- Odronextamab Drug
- Prednisone/prednisolone Drug
- Rituximab Drug
- Vincristine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2023
- Primary completion
- Feb 6, 2028
- Completion
- Nov 2, 2029
- Last update posted
- Mar 10, 2026
2023 – 2029
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center | Tucson | Arizona | 85724 | Recruiting |
| David Geffen School of Medicine at UCLA | Los Angeles | California | 90095 | Recruiting |
| UC Irvine Health | Orange | California | 92868 | Withdrawn |
| Investigative Clinical Research of Indiana | Noblesville | Indiana | 46062 | Recruiting |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | Recruiting |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| Hattiesburg Clinic | Hattiesburg | Mississippi | 39401 | Completed |
| Icahn School of Medicine at Mt Sinai | New York | New York | 10029 | Recruiting |
| Stony Brook University Hospital | Stony Brook | New York | 11794 | Recruiting |
| Clinical Research Alliance Inc | Westbury | New York | 11590 | Withdrawn |
| University of North Carolina | Chapel Hill | North Carolina | 27514 | Recruiting |
| Levine Cancer Institute | Charlotte | North Carolina | 28207 | Recruiting |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | Recruiting |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | Recruiting |
| Center for Oncology and Blood Disorders | Houston | Texas | 77030 | Recruiting |
| HOPE Cancer Center of East Texas | Tyler | Texas | 75701 | Withdrawn |
| Huntsman Cancer Institute - Oncology Division | Salt Lake City | Utah | 84112 | Recruiting |
| University of Virginia | Charlottesville | Virginia | 22908 | Recruiting |
| Virginia Commonwealth University | Richmond | Virginia | 23219 | Withdrawn |
| Prohealth Care Inc | Waukesha | Wisconsin | 53188 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 169 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06091254, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2026 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06091254 live on ClinicalTrials.gov.